Similarly, as multigene assays estimate the risk of recurrence and benefit from chemotherapy in HER2 negative BC, a platform that includes molecular features, such as extent of HER2 addiction, the genomic and molecular makeup of the tumour, intra-tumour heterogeneity, and the immune milieu is required [41]. Here, ERBB2 is linked to neoplasm.